title: Characterization of Intraocular Pressure Increases and Management Strategies Following Treatment With Fluocinolone Acetonide Intravitreal Implants in the FAME Trials.
abstract: To compare elevated intraocular pressure (IOP) management and outcomes among patients with diabetic macular edema who received fluocinolone acetonide (FAc) implants versus sham-control treatment and explore the prior ocular steroid exposure impact on IOP outcomes.
  
  
  
  Best-corrected visual acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study charts or electronic VA testers. Goldmann applanation tonometry was used to measure IOP.
  
  
  
  Elevated IOP was more common in FAc-versus sham control-treated patients. Medication, and less often trabeculoplasty or surgery, was used to lower IOP without affecting VA outcomes. No patient treated with 0.2 µg/day FAc who received prior ocular steroid required IOP-lowering surgery.
  
  
  
  Elevated IOP may occur following FAc implant receipt; however, in the present study, it was manageable and did not impact vision outcomes. Patients previously treated with ocular steroid did not require IOP-lowering surgery following 0.2 µg/day FAc implant administration. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:426-435.].
authors.forename: Richard K
authors.initials: RK
authors.lastname: Parrish
authors.forename: Peter A
authors.initials: PA
authors.lastname: Campochiaro
authors.forename: P Andrew
authors.initials: PA
authors.lastname: Pearson
authors.forename: Ken
authors.initials: K
authors.lastname: Green
authors.forename: Carlo E
authors.initials: CE
authors.lastname: Traverso
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D003930:Diabetic Retinopathy / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D019468:Disease Management; D004305:Dose-Response Relationship, Drug; D004343:Drug Implants; D005260:Female; D005446:Fluocinolone Acetonide / Q000008:administration & dosage / Q000009:adverse effects*; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects / Q000502:physiology*; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000139:chemically induced* / Q000503:physiopathology / Q000628:therapy; D017410:Practice Guidelines as Topic; D013997:Time Factors; D014065:Tonometry, Ocular; D014130:Trabeculectomy / Q000379:methods; D016896:Treatment Outcome; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D000959:Antihypertensive Agents; D004343:Drug Implants; D005938:Glucocorticoids; D005446:Fluocinolone Acetonide